tag:blogger.com,1999:blog-7663181626936078312.post1805023473655701745..comments2024-01-19T17:28:53.966+08:00Comments on Upekha: Lessons In The MakingCT Changhttp://www.blogger.com/profile/11085620064834659684noreply@blogger.comBlogger2125tag:blogger.com,1999:blog-7663181626936078312.post-15623350548972976222012-05-09T18:40:37.846+08:002012-05-09T18:40:37.846+08:00Hi John,
Thanks for the information. I have other...Hi John,<br /><br />Thanks for the information. I have other clinical trial report on using high dose IL-2 and the result was good. I guess the results would always depend on the experience of the doctors and condition of the patient. What worked for one does not necessary work for another.<br /><br />When the cancer has metastasized, it's always an uphill battle.CT Changhttps://www.blogger.com/profile/11085620064834659684noreply@blogger.comtag:blogger.com,1999:blog-7663181626936078312.post-85133937081767205202012-05-09T18:22:06.362+08:002012-05-09T18:22:06.362+08:00I was reading this morning the website of Dr. Nich...I was reading this morning the website of Dr. Nicholas Gonzalez and looked at case reports. I looked at kidney cancer. He states this about interleukin 2.<br /><br />"Renal cell carcinoma, the most common form of kidney cancer, accounts for 90-95% of all cases. In this type, the disease begins in the epithelial lining cells of the proximal tubules and if localized, can be cured in well over 50% of patients with surgery alone. (2) Once the disease metastasizes, it usually spreads quickly with deadly results. Conventional therapies such as chemotherapy and immune modulation offer little benefit. As Harrison’s reports bluntly, “Investigational therapy is first-line treatment for metastatic disease as no immune approach or chemotherapeutic agent has shown significant antitumor activity.” (3) Interleukin-II, once heralded as a miracle cure in the mid 1980’s based on anecdotal evidence, in controlled clinical trials worked no better than placebo."<br /><br />I hope your research is better than this brief report.johnhttps://www.blogger.com/profile/03762916860351997380noreply@blogger.com